Bladder Cancer Trial, Recruiting NCT07225127 Sponsor: University of Washington Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT07225127
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who currently have a confirmed diagnosis of high-grade non-muscle-invasive bladder cancer (a type of bladder cancer that has not grown into the bladder muscle), at a stage classified as Tis, Ta, or T1, based on laboratory analysis of tissue samples
  • People whose tissue sample shows that more than half of the cancer cells are of a specific type called urothelial carcinoma
  • People with a past confirmed diagnosis of high-grade non-muscle-invasive bladder cancer at the same stages listed above
  • People who, within the last 12 months, have received at least one treatment for this type of bladder cancer — either a liquid medication placed directly into the bladder, or a treatment given through the bloodstream

Who may not be able to join:

  • People whose tissue samples (past or current) show certain rare cancer cell types known as plasmacytoid or small cell (neuroendocrine) components
  • People who have previously had their bladder surgically removed or received radiation therapy for bladder cancer
  • People with a history of bladder cancer that had grown into the bladder muscle, or that had spread to other parts of the body
  • People who currently have, or have untreated, urothelial carcinoma in other parts of the urinary tract outside the bladder (such as the ureters or kidney — note: if such a cancer was treated more than two years ago, this may not apply; confirm with trial site)
  • People who are currently incarcerated or in police custody at the time of screening (people wearing a monitoring device may still be considered)
  • People for whom bladder removal surgery would be medically unsafe due to serious health conditions (confirm with trial site)
  • People who cannot tolerate any form of bladder cancer treatment — either directly into the bladder or through the bloodstream
  • People who are unable to provide written consent in English
  • People who cannot be contacted to complete research surveys
  • People who are planning to take part in another clinical trial where treatment details will be kept confidential and unavailable to researchers

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: John L Gore, MD, MS, Fred Hutch/University of Washington Cancer Consortium

Phone: 206-210-4040

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 November 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Patient-reported financial toxicity as measured by the COmprehensive Score for financial Toxicity (COST)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov